How Entresto Works Illustrated Schematic of Its Pharmacological Mechanism

Prescribe sacubitril/valsartan at an initial dose of 49/51 mg twice daily for patients with NYHA Class II–IV heart failure and reduced ejection fraction (HFrEF). Titrate to 97/103 mg twice daily after 2–4 weeks if tolerated. This combination targets dual pathways: neprilysin inhibition and angiotensin II receptor blockade.

Neprilysin degrades vasoactive peptides, including natriuretic peptides, bradykinin, and adrenomedullin. By inhibiting neprilysin, sacubitril increases circulating levels of these peptides, promoting vasodilation, natriuresis, and antifibrotic effects. Valsartan blocks angiotensin II type 1 receptors, suppressing vasoconstriction, sodium retention, and cardiac remodeling.

Clinical evidence from PARADIGM-HF demonstrates a 20% reduction in cardiovascular death or heart failure hospitalization compared to enalapril alone. Monitor serum potassium, creatinine, and blood pressure before and after dose adjustments. Discontinue if symptomatic hypotension or hyperkalemia (K⁺ > 5.5 mmol/L) occurs.

Administer cautiously in patients with hepatic impairment (Child-Pugh C) or those taking strong CYP3A4 inhibitors. Avoid concurrent use with ACE inhibitors due to increased risk of angioedema. Transition from ACE inhibitors or ARBs requires a 36-hour washout period to prevent overlapping blockade of the renin-angiotensin system.

For elderly patients or those with low systolic blood pressure (SBP < 110 mmHg), start with 24/26 mg twice daily. Use clinical response, not ejection fraction alone, to guide therapy in acute decompensated heart failure settings.

How Sacubitril/Valsartan Modulates Cardiovascular Pathways

Initiate therapy with sacubitril/valsartan at 49/51 mg twice daily for patients naïve to renin-angiotensin system (RAS) inhibitors, adjusting to a target dose of 97/103 mg within 2–4 weeks, contingent on blood pressure and renal function tolerability.

Key pharmacological interactions occur at the molecular level:

Neprilysin inhibition (sacubitril): Elevates natriuretic peptides (ANP, BNP, CNP) and bradykinin by preventing their enzymatic degradation, enhancing vasodilation, natriuresis, and myocardial relaxation.
Angiotensin II receptor blockade (valsartan): Antagonizes AT₁ receptors, suppressing vasoconstriction, aldosterone secretion, and cardiac remodeling pathways.

Dual modulation yields synergistic effects:

Reduces hospitalization risk by 21% and cardiovascular death by 20% versus enalapril alone (PARADIGM-HF trial, N Engl J Med 2014).
Lowers N-terminal pro-BNP (NT-proBNP) levels by ≥30% within 2–4 weeks, correlating with improved left ventricular ejection fraction (LVEF) in HFrEF patients.
Attenuates fibrosis and hypertrophy via suppression of TGF-β and collagen synthesis, validated in rodent models and human biopsy studies.

Monitor serum potassium (target: 4.0–5.0 mEq/L) and creatinine (≤2.5 mg/dL) every 2 weeks post-initiation, discontinuing if potassium exceeds 5.5 mEq/L or eGFR drops >30% from baseline. Adjust diuretics empirically if weight fluctuates >2 kg over 3 days.

Contraindications demand rigorous screening:

History of angioedema (risk 0.5% vs. 0.2% with ACE inhibitors).
Concomitant ACE inhibitor use (mandatory 36-hour washout period).
Pregnancy (FDA Category D–fetal toxicity risk).
Severe hepatic impairment (Child-Pugh C) or bile duct obstruction.

Pharmacokinetic considerations include:

Bioavailability: Sacubitril (60%), valsartan (23%).
Metabolism: Sacubitril converted to active LBQ657 via esterases; valsartan minimally metabolized (≤10% via CYP2C9).
Elimination: Primarily renal (52–68% as LBQ657) and biliary (valsartan).
Half-life: LBQ657 (11.5 hours), valsartan (9.9 hours).

Reduce dose by 50% in patients with eGFR 2 or moderate hepatic impairment.

Clinical pearls for optimization:

Titrate more slowly (e.g., 49/51 mg for 4 weeks) in frail patients or those with systolic BP
Combine with SGLT2 inhibitors (empagliflozin) or mineralocorticoid receptor antagonists (spironolactone) for additive benefits–reduces composite HF outcomes by 30–35% in post-hoc analyses.
Avoid nonsteroidal anti-inflammatory drugs (NSAIDs) due to nephrotoxicity risk.
Educate patients on orthostatic hypotension symptoms (dizziness, syncope) and salt substitution (≤2 g sodium/day).

Core Elements of Sacubitril/Valsartan and Their Functional Dynamics

Prescribe sacubitril/valsartan at an initial dose of 49/51 mg twice daily for heart failure with reduced ejection fraction (HFrEF), titrating to 97/103 mg twice daily after 2–4 weeks if tolerated. Sacubitril, a neprilysin inhibitor, blocks the degradation of natriuretic peptides, bradykinin, and adrenomedullin, which collectively enhance vasodilation, natriuresis, and diuresis while reducing myocardial fibrosis and hypertrophy. Valsartan, an angiotensin II receptor blocker (ARB), selectively antagonizes AT₁ receptors, attenuating vasoconstriction, aldosterone release, and sodium retention–effects exacerbated in HFrEF.

Molecular Targets and Clinical Outcomes

Component	Primary Target	Key Effects	Clinical Benefit
Sacubitril	Neprilysin (NEP)	↑ Natriuretic peptides, ↓ endothelial dysfunction	Reduces hospitalization risk by 21% vs. enalapril (PARADIGM-HF)
Valsartan	AT₁ receptor	↓ Afterload, ↓ aldosterone synthesis	Lowers all-cause mortality by 16% vs. placebo (Val-HeFT)

Monitor serum potassium and creatinine 1–2 weeks post-initiation; discontinue if potassium exceeds 5.5 mmol/L or creatinine rises by >50%. The drug’s dual pathway modulation mitigates neurohormonal overactivation–a hallmark of HFrEF–while avoiding bradykinin accumulation risks seen with ACE inhibitors. Sacubitril’s inhibition of neprilysin does not impair ACE-driven bradykinin breakdown, unlike sacubitril’s predecessor omapatrilat, which caused angioedema in 2.17% of patients (OVERTURE trial).

Adjust dosing for renal impairment: reduce starting dose to 24/26 mg twice daily if eGFR is 30–60 mL/min/1.73 m² and avoid in severe hepatic dysfunction (Child-Pugh C). The valsartan component’s selectivity for AT₁ over AT₂ receptors preserves beneficial AT₂-mediated vasodilation and tissue repair, a distinction absent in non-selective ARBs like losartan. Pharmacokinetic synergy between sacubitril (prodrug metabolized to LBQ657) and valsartan achieves peak plasma concentrations in 1.5–2.5 hours, with LBQ657’s half-life of ~12 hours supporting twice-daily administration.

Pharmacodynamic Interactions and Precautions

Avoid concomitant use with ACE inhibitors (e.g., lisinopril) due to angioedema risk, maintaining a 36-hour washout period when switching therapies. The combination’s superiority over enalapril stems from sacubitril’s augmentation of endogenous peptides–ANP, BNP, and CNP–which activate particulate guanylate cyclase, elevating cGMP levels to relax vascular smooth muscle. Unlike β-blockers, sacubitril/valsartan does not depress myocardial contractility, making it safer in acute decompensated heart failure.

Assess blood pressure before each dose adjustment; symptomatic hypotension occurs in 18% of patients (PARADIGM-HF), particularly in volume-depleted states. LBQ657’s inhibition of neprilysin also extends to amyloid-beta degradation, though clinical implications for Alzheimer’s disease remain investigational (EVOKE trial). Store the drug below 30°C, as degradation accelerates at higher temperatures, reducing valsartan’s bioactivity by up to 30% within 6 months.

For patients intolerant to ARBs, consider alternative vasodilators (e.g., hydralazine/isosorbide dinitrate), though these lack neurohormonal modulation. The sacubitril/valsartan formulation’s 1:1 molar ratio optimizes target engagement, with LBQ657’s IC₅₀ for neprilysin at 5.3 nM–fivefold more potent than thiorphan. In post-MI heart failure, data from the PARADISE-MI trial suggest non-inferiority to ramipril, though superiority wasn’t met (HR 0.90, 95% CI 0.78–1.03).

Step-by-Step Molecular Interactions Between Sacubitril/Valsartan and Neurohormonal Regulation

Administer sacubitril/valsartan at the target dose of 97/103 mg twice daily to maximize neprilysin inhibition while maintaining angiotensin II receptor blockade. Sacubitril’s active metabolite, LBQ657, binds irreversibly to neprilysin’s catalytic site within 30 minutes of ingestion, increasing circulating natriuretic peptides by 2- to 3-fold within 4 hours. Concurrently, valsartan occupies the AT₁ receptor, preventing angiotensin II-mediated vasoconstriction and aldosterone release, which drops plasma aldosterone levels by 25–35% after 7 days.

Neprilysin Substrate Dynamics

LBQ657 preferentially elevates brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) over C-type natriuretic peptide (CNP), altering the substrate hierarchy. BNP rises acutely (t₁/₂ ≈ 20 minutes), while ANP increases gradually over 4 weeks, peaking at 120 pg/mL in patients with NYHA class II-III. The differential kinetics stem from neprilysin’s higher affinity for ANP (Km = 0.5 µM) compared to BNP (Km = 2.1 µM), leading to sustained natriuresis and vasodilation. Monitor serum NT-proBNP as a surrogate marker, targeting a ≥30% reduction from baseline to confirm target engagement.

Angiotensin II escapes AT₁ blockade via compensatory upregulation of ACE2, converting it to angiotensin-(1-7). This peptide activates the Mas receptor, enhancing nitric oxide synthase activity in endothelial cells–effects absent with ACE inhibitors. Pair valsartan with beta-blockers to blunt the reflexive rise in renin (typically 2- to 4-fold), which otherwise counteracts the efficacy of dual pathway modulation. Avoid abrupt discontinuation in patients with glomerular filtration rate 5.5 mEq/L).

Bradykinin and Endothelin Crosstalk

Neprilysin inhibition preserves bradykinin, but LBQ657’s substrate selectivity limits bradykinin accumulation to 3× ULN), a complication observed in 8% of combined therapy cases.

Measure serum cGMP 4 weeks post-initiation; values 70 bpm despite maximized beta-blockade, as sacubitril/valsartan alone reduces resting heart rate by only 4–6 bpm.